Annette L. Heroux Net Worth

The estimated Net Worth of Annette Heroux is at least $15.8 millier dollars as of 12 December 2003. Ms Heroux owns over 8,400 units of Icad Inc stock worth over $15,846 and over the last 21 years she sold ICAD stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms Heroux ICAD stock SEC Form 4 insiders trading

Ms has made over 2 trades of the Icad Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently she exercised 8,400 units of ICAD stock worth $6,804 on 12 December 2003.

The largest trade she's ever made was exercising 10,000 units of Icad Inc stock on 12 November 2003 worth over $8,100. On average, Ms trades about 4,600 units every 8 days since 2003. As of 12 December 2003 she still owns at least 11,400 units of Icad Inc stock.

You can see the complete history of Ms Heroux stock trades at the bottom of the page.

Ms. Annette L. Heroux biography

Annette L. Heroux is the VP of Admin. at Icad Inc.

How old is Ms Heroux?

Ms Heroux is 64, she's been the VP of Admin. of Icad Inc since . There are 2 older and 9 younger executives at Icad Inc. The oldest executive at Icad Inc is Michael S. Klein, 67, who is the Exec. Chairman & CEO.

What's Ms Heroux's mailing address?

Annette's mailing address filed with the SEC is 4 TOWNSEND WEST, SUITE 17, NASHUA, NH, 03063.

Insiders trading at Icad Inc

Over the last 22 years, insiders at Icad Inc have traded over $10,970,060 worth of Icad Inc stock and bought 704,596 units worth $1,672,448 . The most active insiders traders include Anthony F Ecock, Nathaniel Dalton et Kevin C Burns. On average, Icad Inc executives and independent directors trade stock every 45 days with the average trade being worth of $39,056. The most recent stock trade was executed by Dana R Brown on 31 March 2023, trading 40,000 units of ICAD stock currently worth $52,000.

What does Icad Inc do?

icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.

Complete history of Ms Heroux stock trades at Icad Inc

Icad Inc executives and stock owners

Icad Inc executives and other stock owners filed with the SEC include:

• Michael S. Klein,
  Exec. Chairman & CEO
• Stacey Stevens,
  President
• Jonathan Go,
  Chief Technology Officer
• Michael Klein,
  Executive Chairman of the Board, Chief Executive Officer
• Stacey M. Stevens,
  Pres
• Jonathan Go,
  Chief Technology Officer
• Andrew Sassine,
  Independent Director
• Susan Wood,
  Independent Director
• Rakesh Patel,
  Independent Director
• Jeremy Feffer,
  Investor Relations Contact Officer
• Nathaniel Dalton,
  Independent Director
• R. Scott Areglado,
  Chief Financial Officer
• Jeffrey Sirek,
  Chief Commercial Officer
• Brian Testa,
  Chief People Officer
• Annette L. Heroux,
  VP of Admin.
• Charles Ross Carter,
  CFO & Sec.
• Rachel Brem,
  Director
• Steven N Rappaport,
  Director
• Robert L Goodman,
  Director
• Dr Lawrence Howard,
  Director
• Anthony F Ecock,
  Director
• Timothy Norris Irish,
  Director
• Richard Christopher,
  Executive VP and CFO
• Andy Sassine,
  Director
• Somu Subramaniam,
  Director
• Elliot J Md Mba Sussman,
  Director
• Kenneth M Ferry,
  President, CEO
• James Harlan,
  Director
• George P Farley,
  Director
• W Scott Parr,
  Chief Executive Officer, Presi
• Herschell Sklaroff,
  Director
• John De Biase,
  Vice President of Sales
• Annette Heroux,
  Chief Financial Officer
• Steven K Rogers,
  Chief Scientific Officer
• Peter Farrell,
  EVP Marketing
• Thomas E Shoup,
  VP, Staff Operations
• James L Corbett,
  Chief Commercial Officer
• Kevin Woods,
  Vice President, Research & Dev
• Samuel Ronci,
  Vice President of Operations
• Robert Howard,
  Director
• Kevin C Burns,
  Executive VP of Finance, CFO
• Darlene M Deptula Hicks,
  Executive VP of Finance, CFO
• Maha Sallam,
  Executive Vice President
• Jeffrey H Barnes,
  Executive VP of Sales
• Dana R Brown,
  See Remarks
• Charles Ross Carter,
  CHIEF FINANCIAL OFFICER
• Hedvig Hricak,
  Director
• Daniel Joseph Shea,
  See Remarks
• Eric Lonnqvist,
  See Remarks
• Michael John Doyle,
  Director